CALCA and migraine disorder: We have recently shown that the intraperitoneal dose of 5 mg/kg GTN is sufficient to increase CGRP release and cause periorbital hypersensitivity in rats [71, 75] as an expression of facial hyperalgesia, a symptom frequently experienced in migraine.